Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Profit After Tax: 2019-2025

Historic Profit After Tax for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to -$7.3 million.

  • Keros Therapeutics' Profit After Tax rose 86.25% to -$7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.4 million, marking a year-over-year increase of 135.50%. This contributed to the annual value of -$187.4 million for FY2024, which is 22.46% down from last year.
  • As of Q3 2025, Keros Therapeutics' Profit After Tax stood at -$7.3 million, which was up 76.28% from -$30.7 million recorded in Q2 2025.
  • Keros Therapeutics' Profit After Tax's 5-year high stood at $148.5 million during Q1 2025, with a 5-year trough of -$53.0 million in Q3 2024.
  • In the last 3 years, Keros Therapeutics' Profit After Tax had a median value of -$39.4 million in 2023 and averaged -$20.9 million.
  • Per our database at Business Quant, Keros Therapeutics' Profit After Tax slumped by 328.21% in 2022 and then soared by 444.32% in 2025.
  • Over the past 5 years, Keros Therapeutics' Profit After Tax (Quarterly) stood at -$6.9 million in 2021, then slumped by 328.21% to -$29.7 million in 2022, then crashed by 35.42% to -$40.2 million in 2023, then decreased by 14.37% to -$46.0 million in 2024, then surged by 86.25% to -$7.3 million in 2025.
  • Its Profit After Tax was -$7.3 million in Q3 2025, compared to -$30.7 million in Q2 2025 and $148.5 million in Q1 2025.